| dc.contributor.author | Hazboun, Nader | |
| dc.date.accessioned | 2018-11-28T09:41:21Z | |
| dc.date.available | 2018-11-28T09:41:21Z | |
| dc.date.issued | 2017-04 | |
| dc.identifier.issn | 10.5923/j.ijtt.20170601.01 | |
| dc.identifier.issn | 10.5923/j.ijtt.20170601.02 | |
| dc.identifier.uri | http://dspace.bethlehem.edu:8080/xmlui/handle/123456789/85 | |
| dc.description.abstract | Cancer treatment for hematological malignancies traditionally included systemic chemotherapy and localized radiotherapy for central nervous system (CNS) disease. These therapies in addition to their adverse effects’ profile do not induce complete responses in all patients. The development of chimeric antigen receptor (CAR) technology enables the targeting of tumors with high affinity and specificity leading to unprecedented responses among refractory/relapsed patients with various blood malignancies. This mini-review summarizes the role of CAR-T cells for the treatment of blood cancer highlighting potential areas of improvements. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Scientific & Academic Publishing | en_US |
| dc.subject | Immunotherapy, Monoclonal antibody, Chimeric antigen receptor T-cells | en_US |
| dc.title | Cancer Immunotherapy with CAR-T cells for Hematological Malignancies | en_US |
| dc.type | Article | en_US |
